Denosumab

Artenix  contains the active substance denosumab, which has a protein structure. This protein (monoclonal IgG2 antibody) specifically and targeted binds to the RANKL. RANKL is a protein that is essential for the formation, function and survival of osteoclasts (bone-resorbing cells). Artenix binds to RANKL and prevents RANKL from binding to its receptor called RANK, which is present on the surface of osteoclast precursors and osteoclasts. This binding prevents the formation, function and survival of osteoclasts, thereby decreasing bone resorption in cortical and trabecular bone, and thereby increasing bone mass and bone strength.

Artenix helps slow down the process of bone destruction in bone cancer (bone metastasis) and, in the treatment of giant cell tumour of bone, it reduces tumour growth.

Uses of Artenix

How to use Artenix

Artenix is available by prescription only. The recommended dose of Artenix in adults is 120mg administrated once every 4 weeks as a subcutaneous injection. If you are being treated for Giant cell tumour of bone, you will receive additional doses of Artenix 1 week and 2 weeks after the first dose. During treatment with Artenix, you are required to take Calcium and Vitamin D supplements. Artenix is injected into the thigh, the abdomen (at least 5cm away from the navel), or the upper arm. Artenix is supplied as a ready-to-use vial containing a clear, colourless to pale yellow solution for injection. Each pack of Artenix contains one vial of solution for injection and one patient information leaflet.